- €4.74m
- €16.99m
- €26.66m
Brief: Friulchem H1 Net Loss EUR 0.1 Mln
Brief: Friulchem FY Net Result Turns To Loss Of EUR 299,000
Brief: Friulchem H1 Net Loss Widens To EUR 89,000
Brief: Friulchem Approves EUR 3.5 Mln Supply Deal With Evultis
Brief: Friulchem FY Net Profit Shrinks To EUR 33,000
Brief: Friulchem's Unit Buys 70% Of Arcanatura Through EUR 400,000 Capital Increase
Brief: Friulchem H1 Net Loss Shrinks To EUR 39,000
Brief: Friulchem FY Net Profit At EUR 0.08 Mln
Brief: Friulchem To Issue Non-Convertible Bond For EUR 2.5 Mln
Brief: Friulchem H1 Net Loss Shrinks To EUR 56,000
Brief: Friulchem Signs Prelim. Deal To Buy Virbac's Branch
Brief: Friulchem Approves Framework Deal On Supply Contract With Evultis
Brief: Friulchem FY Net Result Turns To Loss Of EUR 0.3 Mln
Brief: Friulchem H1 Net Result Turns To Loss Of EUR 404,000
Brief: Friulchem Obtains Tax Benefit Of EUR 338,814.75 To Cover Part Of IPO Costs
Brief: Friulchem Board Approves Framework Agreement With Evultis
Brief: Friulchem Board Approves Framework Agreement With Evultis
Brief: Friulchem Orders Prednisolone For EUR 551,000 From Shareholder Evultis
Brief: Friulchem To Start Launch And Distribution Of Human-Use Antibiotic In South Africa